Is IMTX or COGT more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Immatics -572.35% -47.36% -39.35% Cogent Biosciences N/A -104.27% -54.64%

Does the media prefer IMTX or COGT?

In the previous week, Cogent Biosciences had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Immatics. Cogent Biosciences' average media sentiment score of 0.40 beat Immatics' score of 0.18 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IMTX or CNTA?

In the previous week, Immatics and Immatics both had 1 articles in the media. Immatics' average media sentiment score of 0.18 beat Centessa Pharmaceuticals' score of 0.00 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, SRRK or IMTX?

Immatics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Immatics $37.30M 34.37 -$222.26M -$1.99 N/A

Is SRRK or IMTX more profitable?

Scholar Rock has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Immatics -572.35% -47.36% -39.35%

Does the media favor SRRK or IMTX?

In the previous week, Scholar Rock had 3 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Scholar Rock and 1 mentions for Immatics. Scholar Rock's average media sentiment score of 1.54 beat Immatics' score of 0.18 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMTX or MIRM?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 1 mentions for Immatics. Mirum Pharmaceuticals' average media sentiment score of 0.37 beat Immatics' score of 0.18 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, IMTX or TGTX?

TG Therapeutics has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immatics $37.30M 34.37 -$222.26M -$1.99 N/A TG Therapeutics $700.35M 9.12 $447.18M $2.86 14.59

Is IMTX or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Immatics' net margin of -572.35%. TG Therapeutics' return on equity of 88.73% beat Immatics' return on equity. Company Net Margins Return on Equity Return on Assets Immatics -572.35% -47.36% -39.35% TG Therapeutics 65.95% 88.73% 43.44%

Does the media refer more to IMTX or TGTX?

In the previous week, TG Therapeutics had 9 more articles in the media than Immatics. MarketBeat recorded 10 mentions for TG Therapeutics and 1 mentions for Immatics. TG Therapeutics' average media sentiment score of 0.61 beat Immatics' score of 0.18 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Immatics (IMTX) Competitors

$9.56 -0.23 (-2.35%)

As of 12:08 PM Eastern

Compare

IMTX vs. COGT, CNTA, SRRK, MIRM, and TGTX

Should you buy Immatics stock or one of its competitors? MarketBeat compares Immatics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immatics include Cogent Biosciences (COGT), Centessa Pharmaceuticals (CNTA), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

How does Immatics compare to Cogent Biosciences?

Immatics (NASDAQ:IMTX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Immatics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$37.30M	34.37	-$222.26M	-$1.99	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Cogent Biosciences had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Immatics. Cogent Biosciences' average media sentiment score of 0.40 beat Immatics' score of 0.18 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Immatics currently has a consensus price target of $20.80, indicating a potential upside of 117.57%. Cogent Biosciences has a consensus price target of $43.73, indicating a potential upside of 38.38%. Given Immatics' higher probable upside, equities research analysts clearly believe Immatics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

64.4% of Immatics shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cogent Biosciences has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Immatics beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Immatics compare to Centessa Pharmaceuticals?

Immatics (NASDAQ:IMTX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

64.4% of Immatics shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Immatics presently has a consensus target price of $20.80, indicating a potential upside of 117.57%. Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 4.24%. Given Immatics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Immatics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, Immatics and Immatics both had 1 articles in the media. Immatics' average media sentiment score of 0.18 beat Centessa Pharmaceuticals' score of 0.00 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Immatics. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$37.30M	34.37	-$222.26M	-$1.99	N/A
Centessa Pharmaceuticals	$15M	394.47	-$197.53M	-$1.79	N/A

Summary

Immatics beats Centessa Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Immatics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Scholar Rock currently has a consensus target price of $56.00, suggesting a potential upside of 27.21%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 117.57%. Given Immatics' higher probable upside, analysts plainly believe Immatics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Immatics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Immatics	-572.35%	-47.36%	-39.35%

In the previous week, Scholar Rock had 3 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Scholar Rock and 1 mentions for Immatics. Scholar Rock's average media sentiment score of 1.54 beat Immatics' score of 0.18 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Immatics	$37.30M	34.37	-$222.26M	-$1.99	N/A

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Scholar Rock and Immatics tied by winning 8 of the 16 factors compared between the two stocks.

How does Immatics compare to Mirum Pharmaceuticals?

Immatics (NASDAQ:IMTX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 1 mentions for Immatics. Mirum Pharmaceuticals' average media sentiment score of 0.37 beat Immatics' score of 0.18 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Immatics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$37.30M	34.37	-$222.26M	-$1.99	N/A
Mirum Pharmaceuticals	$569.61M	9.95	-$23.36M	-$13.61	N/A

Immatics currently has a consensus target price of $20.80, indicating a potential upside of 117.57%. Mirum Pharmaceuticals has a consensus target price of $137.64, indicating a potential upside of 48.11%. Given Immatics' higher probable upside, analysts plainly believe Immatics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has a net margin of -140.24% compared to Immatics' net margin of -572.35%. Mirum Pharmaceuticals' return on equity of -11.28% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

64.4% of Immatics shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Mirum Pharmaceuticals beats Immatics on 11 of the 17 factors compared between the two stocks.

How does Immatics compare to TG Therapeutics?

Immatics (NASDAQ:IMTX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

TG Therapeutics has a net margin of 65.95% compared to Immatics' net margin of -572.35%. TG Therapeutics' return on equity of 88.73% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
TG Therapeutics	65.95%	88.73%	43.44%

Immatics currently has a consensus price target of $20.80, indicating a potential upside of 117.57%. TG Therapeutics has a consensus price target of $52.50, indicating a potential upside of 25.80%. Given Immatics' higher possible upside, research analysts clearly believe Immatics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, TG Therapeutics had 9 more articles in the media than Immatics. MarketBeat recorded 10 mentions for TG Therapeutics and 1 mentions for Immatics. TG Therapeutics' average media sentiment score of 0.61 beat Immatics' score of 0.18 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immatics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

64.4% of Immatics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$37.30M	34.37	-$222.26M	-$1.99	N/A
TG Therapeutics	$700.35M	9.12	$447.18M	$2.86	14.59

Summary

TG Therapeutics beats Immatics on 13 of the 17 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMTX vs. The Competition

Export

Metric	Immatics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.28B	$3.32B	$6.47B	$12.13B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-4.81	19.26	23.95	23.84
Price / Sales	34.37	176.98	486.59	88.09
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	2.34	8.12	10.43	6.77
Net Income	-$222.26M	$23.89M	$3.57B	$337.72M
7 Day Performance	-14.18%	-5.34%	-0.97%	-2.97%
1 Month Performance	-15.92%	2.55%	3.55%	1.70%
1 Year Performance	60.13%	37.30%	24.16%	27.34%

Immatics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMTX Immatics	3.0216 of 5 stars	$9.56 -2.3%	$20.80 +117.6%	+64.0%	$1.28B	$37.30M	N/A	260
COGT Cogent Biosciences	3.0626 of 5 stars	$33.10 -4.9%	$43.73 +32.1%	+356.2%	$5.97B	N/A	N/A	80	Gap Up
CNTA Centessa Pharmaceuticals	1.5945 of 5 stars	$39.93 +0.2%	$41.33 +3.5%	+232.4%	$5.93B	$15M	N/A	200	Positive News
SRRK Scholar Rock	3.3487 of 5 stars	$45.36 -4.3%	$56.00 +23.5%	+29.4%	$5.91B	N/A	N/A	140	Positive News
MIRM Mirum Pharmaceuticals	3.3751 of 5 stars	$92.64 -3.8%	$137.64 +48.6%	+101.6%	$5.87B	$569.61M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMTX) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immatics (IMTX) Competitors

IMTX vs. COGT, CNTA, SRRK, MIRM, and TGTX

How does Immatics compare to Cogent Biosciences?

Summary

How does Immatics compare to Centessa Pharmaceuticals?

Summary

How does Immatics compare to Scholar Rock?

Summary

How does Immatics compare to Mirum Pharmaceuticals?

Summary

How does Immatics compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immatics (IMTX) Competitors

IMTX vs. COGT, CNTA, SRRK, MIRM, and TGTX

How does Immatics compare to Cogent Biosciences?

Which has stronger earnings and valuation, IMTX or COGT?

Does the media prefer IMTX or COGT?

Which has more risk & volatility, IMTX or COGT?

Do analysts rate IMTX or COGT?

Do insiders & institutionals have more ownership in IMTX or COGT?

Is IMTX or COGT more profitable?

Summary

How does Immatics compare to Centessa Pharmaceuticals?

Do insiders & institutionals believe in IMTX or CNTA?

Is IMTX or CNTA more profitable?

Do analysts rate IMTX or CNTA?

Does the media refer more to IMTX or CNTA?

Which has more volatility and risk, IMTX or CNTA?

Which has stronger earnings & valuation, IMTX or CNTA?

Summary

How does Immatics compare to Scholar Rock?

Do analysts prefer SRRK or IMTX?

Which has more risk and volatility, SRRK or IMTX?

Is SRRK or IMTX more profitable?

Does the media favor SRRK or IMTX?

Which has stronger earnings & valuation, SRRK or IMTX?

Do institutionals and insiders hold more shares of SRRK or IMTX?

Summary

How does Immatics compare to Mirum Pharmaceuticals?

Does the media prefer IMTX or MIRM?

Which has more volatility and risk, IMTX or MIRM?

Which has preferable valuation & earnings, IMTX or MIRM?

Do analysts prefer IMTX or MIRM?

Is IMTX or MIRM more profitable?

Do institutionals & insiders have more ownership in IMTX or MIRM?

Summary

How does Immatics compare to TG Therapeutics?

Is IMTX or TGTX more profitable?

Do analysts prefer IMTX or TGTX?

Does the media refer more to IMTX or TGTX?

Which has more volatility & risk, IMTX or TGTX?

Do institutionals and insiders believe in IMTX or TGTX?

Which has preferable valuation & earnings, IMTX or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools